Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-08-13 DOI:10.1080/14737140.2023.2247565

Piotr Rutkowski, Anna M Czarnecka

{"title":"Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma.","authors":"Piotr Rutkowski, Anna M Czarnecka","doi":"10.1080/14737140.2023.2247565","DOIUrl":null,"url":null,"abstract":"Introduction: Up to 30% of patients with stage IIB and 50% of stage IIC melanoma experience recurrence within 5 years after radical surgery. Adjuvant treatment is expected to improve this prognosis.Areas covered: Pembrolizumab (MK-3475) is a humanized monoclonal antibody that acts against the programmed cell death 1 (PD-1) receptor. Pembrolizumab was first approved in monotherapy for the treatment of unresectable/metastatic melanoma based on the results of the prospective KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006 trials. KEYNOTE-716 is the randomized phase III trial of pembrolizumab treatment in resected stage II melanoma. Treatment with pembrolizumab is statistically significant, reducing the risk of recurrence as well as distant metastases risk after primary tumor resection. Pembrolizumab treatment has a 24-month RFS rate of 81.2% (HR 0.64 vs placebo) and a DMFS rate of 88.1%.Expert opinion: 1-year adjuvant pembrolizumab treatment of stage IIB/C melanoma patients significantly reduces recurrence or death risk. The safety profile of adjuvant treatment is not different from previously reported and is manageable. Longer follow-up is required to fully understand the efficacy and safety of adjuvant therapy for stage II melanoma, as the number of patients needed to treat is twice as high as for stage III patients.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 9","pages":"897-902"},"PeriodicalIF":2.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2023.2247565","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Introduction: Up to 30% of patients with stage IIB and 50% of stage IIC melanoma experience recurrence within 5 years after radical surgery. Adjuvant treatment is expected to improve this prognosis.

Areas covered: Pembrolizumab (MK-3475) is a humanized monoclonal antibody that acts against the programmed cell death 1 (PD-1) receptor. Pembrolizumab was first approved in monotherapy for the treatment of unresectable/metastatic melanoma based on the results of the prospective KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006 trials. KEYNOTE-716 is the randomized phase III trial of pembrolizumab treatment in resected stage II melanoma. Treatment with pembrolizumab is statistically significant, reducing the risk of recurrence as well as distant metastases risk after primary tumor resection. Pembrolizumab treatment has a 24-month RFS rate of 81.2% (HR 0.64 vs placebo) and a DMFS rate of 88.1%.

Expert opinion: 1-year adjuvant pembrolizumab treatment of stage IIB/C melanoma patients significantly reduces recurrence or death risk. The safety profile of adjuvant treatment is not different from previously reported and is manageable. Longer follow-up is required to fully understand the efficacy and safety of adjuvant therapy for stage II melanoma, as the number of patients needed to treat is twice as high as for stage III patients.

查看原文本刊更多论文

Pembrolizumab用于IIB或IIC黑色素瘤的辅助治疗。

引言：高达30%的IIB期和50%的IIC期黑色素瘤患者在5年内复发根治性手术后数年。辅助治疗有望改善这种预后。涵盖领域：Pembrolizumab（MK-3475）是一种人源化单克隆抗体，可对抗程序性细胞死亡1（PD-1）受体。根据前瞻性KEYNOTE-001、KEYNOTE-002和KEYNOTE-006试验的结果，Pembrolizumab首次被批准用于单药治疗不可切除/转移性黑色素瘤。KEYNOTE-716是pembrolizumab治疗切除的II期黑色素瘤的随机III期试验。pembrolizumab治疗具有统计学意义，可降低原发性肿瘤切除后复发风险和远处转移风险。Pembrolizumab治疗24个月的RFS发生率为81.2%（HR 0.64 vs安慰剂），DMFS发生率为88.1%。专家意见：对IIB/C期黑色素瘤患者进行1年辅助治疗可显著降低复发或死亡风险。辅助治疗的安全性与之前报道的没有什么不同，并且是可控的。需要更长的随访时间来充分了解辅助治疗II期黑色素瘤的疗效和安全性，因为需要治疗的患者数量是III期患者的两倍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.